Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323824 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL5315326 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL1172743 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL3359435 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL2034678 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL8295172 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL5217474 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL323823 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089207 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089203 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4016204-A | ISOMERIZING ETHYL-2-PHENYL-CYCLOPROPANE CARBOXYLATE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1977-04-05 | — | — | US | claimed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| WO-2025215536-A1 | MACROCYCLIC PANRAS INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |
| EP-4617264-A1 | ISOINDOLINONE DERIVATIVE HAVING ARYLCYCLOALKYLAMIDE STRUCTURE, AND USE THEREOF | Oncord Bio Inc (KR) | 2025-09-17 | — | — | EP | disclosed |
| CN-112867705-B | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3774722-B1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| WO-2024101763-A1 | ISOINDOLINONE DERIVATIVE HAVING ARYLCYCLOALKYLAMIDE STRUCTURE, AND USE THEREOF | 주식회사 온코드바이오 | 2024-05-16 | — | — | WO | disclosed |
| EP-4284802-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023125846-A1 | COMPOUND FOR PREVENTING AND TREATING CORONAVIRUS INFECTION, CONJUGATE THEREOF AND METHOD THEREFOR | 苏州爱科百发生物医药技术有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| EP-0436199-B1 | Cyclopropyl derivative lipoxygenase inhibitors | ABBOTT LAB (US) | 1994-08-03 | — | — | EP | disclosed |
| WO-1992020665-A1 | THIAZOLIDINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXO GROUP LIMITED (GB) | 1992-11-26 | — | — | WO | disclosed |
| US-5120752-A | N-(1-(20(3-pyridyloxy)phenyl)cyclopropyl) alkyl-N-hydroxyurea compounds, antiinflammatory agents | ABBOTT LABORATORIES (US) | 1992-06-09 | — | — | US | disclosed |
| US-5037853-A | Antiinflammatory agents | ABBOTT LABORATORIES (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0436199-A1 | Cyclopropyl derivative lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1991-07-10 | — | — | EP | disclosed |
| US-4016204-A | ISOMERIZING ETHYL-2-PHENYL-CYCLOPROPANE CARBOXYLATE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | FFAR1 4027/4885HDAC4 819/4885ALDH1A1 621/4885 |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | FFAR1 3769/4885HDAC4 745/4885ALDH1A1 4411/4885 |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | GRM5, GRM1, GRIN1 | FFAR1 74/4885HDAC4 1082/4885ALDH1A1 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.